Asembia Summit: IRA Drug Negotiation to Reshape Medicare Part B and Commercial Healthcare Delivery

Panelists at Asembia’s AXS25 Summit discussed the Inflation Reduction Act’s (IRA) drug negotiation provisions, highlighting their potential to significantly alter Medicare drug pricing, provider reimbursement, and healthcare delivery models within both Part B and commercial markets. The discussions at the summit suggest the IRA’s drug negotiation measures will likely have a ripple effect. Specifically, the panelists noted the law’s impact will extend beyond just drug costs. They expect it to reshape how Medicare Part B providers are reimbursed and influence the overall structure of healthcare delivery in both the Medicare system and the broader commercial healthcare landscape.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

Author

Mark Chiang